The complaint, filed June 22, alleges Pfizer breached Enanta’s patent that “discloses and claims compounds and pharmaceutically acceptable salts which inhibit coronavirus replication activity, and methods of treating a coronavirus infection.” The targeted ingredient is Paxlovid’s nirmatrelvir tablets, according to the suit.
Pfizer did not immediately respond to requests for comment.
Enanta filed the patent in July 2020, two years before the U.S. Patent and Trademark Office approved it, according to a press release. The Watertown, Mass.-based business said it recognizes the importance of the nation’s most popular COVID-19 treatment and does not seek to block the “production, sale or distribution” of Paxlovid.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
